SCHEMBL6097111

SCHEMBL6097111

O=C1C=C(c2cn(S(=O)(=O)c3cccs3)c3ccccc23)C(=O)N1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 7/20 0.47
POLB P06746 1/20 0.44
CYP3A4 P08684 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTT P42858 1/20 0.43
PRKCA P17252 1/20 0.38
GSK3B P49841 1/20 0.38
KLK7 P49862 1/20 0.38
LMNA P02545 1/20 0.38
HPGD P15428 1/20 0.38
CA12 O43570 3/20 0.36
CA9 Q16790 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
PKM P14618 1/20 0.36
IDE P14735 1/20 0.36
CA2 P00918 2/20 0.36
KCNN4 O15554 1/20 0.36
KCNA3 P22001 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6098330 0.78 L3MBTL1 (0.62) HTR6KLK7CA12CA9L3MBTL1
SCHEMBL6099550 0.76 HTR6 (0.46) HTR6CA12CA9L3MBTL1CA2
SCHEMBL6097509 0.75 GAA (0.46) HTR6POLBLMNACA9PKM
SCHEMBL6111241 0.72 HTR6 (0.54) HTR6LMNACA12CA9L3MBTL1
SCHEMBL3600677 0.71 KDM4E (0.46) POLBPRKCAGSK3BHPGD
SCHEMBL6099312 0.71 HTR6 (0.52) HTR6PRKCAGSK3BCA9L3MBTL1
SCHEMBL5879232 0.71 CCNE2 (0.63) PRKCAGSK3B
SCHEMBL29504831 0.71 CCNE2 (0.63) PRKCAGSK3B
Hydrochloric Acid SCHEMBL29664072 0.70 CCNE2 (0.61) PRKCAGSK3B
SCHEMBL6111662 0.69 HTR6 (0.45) HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF HTR6 765/4885POLB 375/4885CYP3A4 4436/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF HTR6 883/4885POLB 346/4885CYP3A4 4313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.